Nanocurcumin preserves kidney function and haematology parameters in DMBA-induced ovarian cancer treated with cisplatin via its antioxidative and anti-inflammatory effect in rats

References

• Alizadeh M, Kheirouri S. 2019. Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: a comprehensive meta-analysis of randomized controlled trials. Biomedicine. 9(4):22–23.
   PubMedGoogle Scholar
• Amano T, Chano T, Isono T, Kimura F, Kushima R, Murakami T. 2019. Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers. World J Surg Onc. 17(1):1–7.
   PubMedGoogle Scholar
• Amano T, Murakami A, Murakami T, Chano T. 2021. Antioxidants and therapeutic targets in ovarian clear cell carcinoma. Antioxidants. 10(2):115–187.
   Web of Science ®Google Scholar
• Antonucci E, Lippi G, Ticinesi A, Pigna F, Guida L, Morelli I, Nouvenne A, Borghi L, Meschi T. 2014. Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker for the early diagnosis of acute kidney injury (AKI). Acta Biomed. 85(3):289–294.
   PubMedGoogle Scholar
• Appiah-Opong R, Commandeur JNM, van Vugt-Lussenburg B, Vermeulen NPE. 2007. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology. 235(1-2):83–91.
   PubMed Web of Science ®Google Scholar
• Arita M, Watanabe S, Aoki N, Kuwahara S, Suzuki R, Goto S, Abe Y, Takahashi M, Sato M, Hokari S, et al. 2021. Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. Sci Rep. 11(1):710–750.
   PubMed Web of Science ®Google Scholar
• Arozal W, Louisa M, Rahmat D, Chendrana P, Sandhiutami NMD. 2021. Development, characterization, and pharmacokinetic profile of chitosan-sodium tripolyphosphate nanoparticle-based drug delivery systems for curcumin. Adv Pharm Bull. 11(1):77–85.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, Zarrin V, Moghadam ER, Hashemi F, Makvandi P, Samarghandian S, Khan H, Hashemi F, et al. 2020. Toward regulatory effects of curcumin on transforming growth factor-beta across different diseases: a review. Front Pharmacol. 11:585413–585413.
   PubMed Web of Science ®Google Scholar
• Bahramsoltani R, Rahimi R, Farzaei MH. 2017. Pharmacokinetic interactions of curcuminoids with conventional drugs: a review. J Ethnopharmacol. 209:1–12.
   PubMed Web of Science ®Google Scholar
• Bamba Y, Yun YS, Kunugi A, Inoue H. 2011. Compounds isolated from Curcuma aromatica Salisb. inhibit human P450 enzymes. J Nat Med. 65(3-4):583–587.
   PubMed Web of Science ®Google Scholar
• Ben Ayed W, Ben Said A, Hamdi A, Mokrani A, Masmoudi Y, Toukabri I, Limayem I, Yahyaoui Y. 2020. Toxicity, risk factors, and management of cisplatin-induced toxicity: a prospective study. J Oncol Pharm Pract. 26(7):1621–1629.
   PubMed Web of Science ®Google Scholar
• Chen S, Gao W, Zhang MJ, Chan JY, Wong TS. 2019. Curcumin enhances cisplatin sensitivity by suppressing NADPH oxidase 5 expressions in human epithelial cancer. Oncol Lett. 18(2):2132–2139.
   PubMed Web of Science ®Google Scholar
• Dwi Sandhiutami NM, Arozal W, Louisa M, Rahmat D, Wuyung PE, Ulum MF. 2018. Induction of epithelial ovarian cancer by implantation of 7,12-dimethylbenz(a)anthracene (DMBA) coated silk in rats. JYP. 11(1):56–61.
   Web of Science ®Google Scholar
• El-Gizawy MM, Hosny EN, Mourad HH, Razik A-E, Amira N. 2020. Curcumin nanoparticles ameliorate hepatotoxicity and nephrotoxicity induced by cisplatin in rats. Naunyn Schmiedebergs Arch Pharmacol. 393(10):1941–1953.
   PubMed Web of Science ®Google Scholar
• Fang C-y, Lou D-y, Zhou L-q, Wang J-c, Yang B, He Q-j, Wang J-j, Weng Q-j 2021. Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 42(12):1951–1969.
   PubMed Web of Science ®Google Scholar
• Higuchi K, Yanagawa T. 2019. Evaluating the dose of cisplatin responsible for causing nephrotoxicity. PLoS One. 14(4):e0215757.
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang W, Wang Y, Zheng Y, Cong Q, Xu C. 2012. Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat. J Ovarian Res. 5(1):1–8.
   PubMedGoogle Scholar
• Kumar P, Barua CC, Sulakhiya K, Sharma RK. 2017. Curcumin ameliorates cisplatin-induced nephrotoxicity and potentiates its anticancer activity in SD rats: potential role of curcumin in breast cancer chemotherapy. Front Pharmacol. 8(132):112–132.
   PubMedGoogle Scholar
• Lee H-Y, Kim S-W, Lee G-H, Choi M-K, Chung H-W, Lee Y-C, Kim H-R, Kwon HJ, Chae H-J. 2017. Curcumin and Curcuma longa L. extract ameliorates lipid accumulation by regulating the endoplasmic reticulum redox and ER stress. Sci Rep. 7(1):6513–6514. 1
   PubMedGoogle Scholar
• Lheureux S, Braunstein M, Oza AM. 2019. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 69(4):280–304.
   PubMed Web of Science ®Google Scholar
• Made Dwi Sandhiutam N, Arozal W, Louisa M, Rahmat D. 2021. Determine curcumin concentration in organ rats and in ovaries at ovarian cancer model rats using ultra-performance liquid chromatography-mass spectrometry (MS)/MS. Pharm Sci Asia. 48(1):37–45.
   Google Scholar
• McSweeney KR, Gadanec LK, Qaradakhi T, Ali BA, Zulli A, Apostolopoulos V. 2021. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers. 13(7):1542–1572.
   PubMed Web of Science ®Google Scholar
• Mikuła-Pietrasik J, Witucka A, Pakuła M, Uruski P, Begier-Krasińska B, Niklas A, Tykarski A, Książek K. 2019. Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. Cell Mol Life Sci. 76(4):681–697.
   PubMed Web of Science ®Google Scholar
• Naik SR, Thakare VN, Patil SR. 2011. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity, and cardiotoxicity in rats: evidence of its antioxidant property. Exp Toxicol Pathol. 63(5):419–431.
   PubMedGoogle Scholar
• Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. 2017. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 34(6):103–110.
   PubMed Web of Science ®Google Scholar
• Perše M, Večerić-Haler Ž. 2018. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int. 2018(1462802):1462802–1462829.
   PubMedGoogle Scholar
• Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. 2019. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 32(8):1469–1486.
   PubMed Web of Science ®Google Scholar
• Quintanilha J, Sousa V, Visacri M, Amaral L, Santos R, Zambrano T, Salazar L, Moriel P. 2017. Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. Cancer Chemother Pharmacol. 80(2):223–233.
   PubMed Web of Science ®Google Scholar
• Rajendran G, Taylor JA, Woolbright BL. 2021. Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer. Cancer Drug Resist. 4:69–84.
   PubMedGoogle Scholar
• Ruggiero A, Trombatore G, Triarico S, Capozza MA, Coccia P, Attina G, Mastrangelo S, Maurizi P. 2019. Cisplatin toxicity in children with malignancy. Biomed Pharmacol J. 12(04):1603–1611.
   Google Scholar
• Sandhiutami NMD, Arozal W, Louisa M, Rahmat D, Wuyung PE. 2020. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA. Front Pharmacol. 11(603235):603213–603235.
   Google Scholar
• Shamsi S, Chen Y, Lim LY. 2015. Characterization and biological properties of NanoCUR formulation and its effect on major human cytochrome P450 enzymes. Int J Pharm. 495(1):194–203.
   PubMedGoogle Scholar
• Shang W, Wang Z. 2017. The update of NGAL in acute kidney injury. Curr Protein Pept Sci. 18(12):1211–1217.
   PubMed Web of Science ®Google Scholar
• Shea K, Stewart S, Rouse R. 2014. Assessment standards: comparing histopathology, digital image analysis, and stereology for early detection of experimental cisplatin-induced kidney injury in rats. Toxicol Pathol. 42(6):1004–1015.
   PubMed Web of Science ®Google Scholar
• Soetikno V, Sari SDP, Ul Maknun L, Sumbung NK, Rahmi DNI, Pandhita BAW, Louisa M, Estuningtyas A. 2019. Pretreatment with curcumin ameliorates cisplatin-induced kidney damage by suppressing kidney inflammation and apoptosis in rats. Drug Res. 69(2):75–82.
   PubMed Web of Science ®Google Scholar
• Vitzthum LK, Heide ES, Park H, Williamson CW, Sheridan P, Huynh-Le M-P, Sirak I, Wei L, Tarnawski R, Mahantshetty U. 2020. Comparison of hematologic toxicity and bone marrow compensatory response in head and neck vs. cervical cancer patients undergoing chemoradiotherapy. Front Oncol. 10(1179):1–9.
   PubMedGoogle Scholar
• Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, Arsenijevic N. 2019. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 26(1):14–25.
   PubMedGoogle Scholar
• Webb PM, Jordan SJ. 2017. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14.
   PubMed Web of Science ®Google Scholar
• Yang Q, Gao L, Hu X, Wang J, Zhang Y, Dong Y, Lan HY, Meng X. 2021. Smad3-targeted therapy protects against cisplatin-induced AKI by attenuating programmed cell death and inflammation via a NOX4-dependent mechanism. Kidney Dis. 7(5):372–390.
   Google Scholar
• Younus H. 2018. Therapeutic potentials of superoxide dismutase. Int J Health Sci. 12(3):88–93.
   PubMed Web of Science ®Google Scholar